Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver

References

• Transfus Med Hemother. (2009). 5 Human albumin. Transfus Med Hemother 36:399–407.
   PubMedGoogle Scholar
• Brown RP, Delp MD, Lindstedt SL, et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–84.
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–71.
   PubMed Web of Science ®Google Scholar
• Di L, Feng B, Goosen TC, et al. (2013). A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos 41:1975–93.
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K, Murayama N, Yamazaki H. (2011). Drug metabolism and toxicity in chimeric mice with humanized liver. J Health Sci 57:22–7.
   Google Scholar
• Inoue T, Sugihara K, Ohshita H, et al. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153–60.
   PubMed Web of Science ®Google Scholar
• Jones RD, Jones HM, Rowland M, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 100:4074–89.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S. (2016). Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica 46:557–69.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Chijiwa H, et al. (2017). Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica 47:382–93.
   PubMed Web of Science ®Google Scholar
• Kato K, Ohbuchi M, Hamamura S, et al. (2015). Development of murine Cyp3a knockout chimeric mice with humanized liver. Drug Metab Dispos 43:1208–17.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–10.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Okumura H, et al. (2005). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333–40.
   PubMed Web of Science ®Google Scholar
• Lave T, Dupin S, Schmitt C, et al. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584–90.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53:167–77.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, et al. (2017). Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica 47:1052–63.
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Paull JD, Richmond BH, et al. (1986). Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22:587–93.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kimura S, et al. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–24.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Yoshitsugu H, Yokoi T, et al. (2005). Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 35:877–90.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. (2002). Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358–70.
   PubMed Web of Science ®Google Scholar
• Preissner S, Kroll K, Dunkel M, et al. (2010). SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 38:D237–43.
   PubMed Web of Science ®Google Scholar
• Ridgway D, Tuszynski JA, Tam YK. (2003). Reassessing models of hepatic extraction. J Biol Phys 29:1–21.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090–110.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Leahy D, Rowland M. (2005). Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–76.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. (2006). Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–57.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Horiguchi A, Sugihara K, et al. (2012). Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 40:322–8.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Naritomi Y, Fujimoto M, et al. (2015). Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica 45:605–14.
   PubMed Web of Science ®Google Scholar
• Sayama H, Komura H, Kogayu M, Iwaki M. (2013). Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics. J Pharm Sci 102:4193–204.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fuse K, Okudaira K, et al. (2005). Contribution of OATP (Organic Anion-Transporting Polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477–81.
   PubMed Web of Science ®Google Scholar
• Tang H, Hussain A, Leal M, et al. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–93.
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. (2005). A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297–303.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12.
   PubMed Web of Science ®Google Scholar
• Wajima T, Fukumura K, Yano Y, Oguma T. (2002). Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci 91:2489–99.
   PubMed Web of Science ®Google Scholar
• Wajima T, Fukumura K, Yano Y, Oguma T. (2003). Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J Pharm Pharmacol 55:939–49.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–62.
   PubMed Web of Science ®Google Scholar
• Waters NJ, Lombardo F. (2010). Use of the Øie-Tozer model in understanding mechanisms and determinants of drug distribution. Drug Metab Dispos 38:1159–65.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Kuribayashi S, Inoue T, et al. (2010). Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152–8.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Mitsui M, et al. (2016). Combining chimeric mice with humanized liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem Res Toxicol 29:1903–11.
   PubMed Web of Science ®Google Scholar